Cash, cash equivalents and marketable securities totaled $99.2 million as of March 31, 2026. We expect the combination of current cash, cash equivalents and marketable securities will be sufficient to fund our operating and capital expenditures into the first quarter of 2027.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GOSS:
- Gossamer Bio Investors File Securities Lawsuit Over Alleged Misstatements About Phase 3 Drug Trial
- GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit – Investors With Losses May Seek to Lead the Class Action After Analysts Allegedly Misled by Trial Claims: Levi & Korsinsky
- Gossamer Bio Receives Nasdaq Minimum Bid Price Deficiency Notice
- Gossamer Bio Lawsuit: Investors Allege Misleading Statements Ahead of Failed PAH Trial
- Morning Movers: Apogee surges following APEX clinical trial readout